Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Next Previous
Drug Profile

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: Anti-PD-L1 monoclonal antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group; APL 502; CBT-502; PD-L1 antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group​; TQ-B2450

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apollomics; Crown Bioscience
  • Developer Apollomics; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Preregistration Endometrial cancer
  • Phase III Biliary cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Squamous cell cancer
  • Phase II/III Adenocarcinoma; Gastric cancer
  • Phase II Diffuse large B cell lymphoma; Gynaecological cancer; Hepatitis B; Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Uterine cancer
  • Phase I/II Acral lentiginous melanoma; Cholangiocarcinoma
  • Preclinical Solid tumours
  • No development reported Triple negative breast cancer

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Injection)
  • 07 Apr 2025 Chia Tai Tianqing Pharmaceutical Group initiates enrolment in a phase II trial in Small cell lung cancer (Combination therapy, First line therapy, Late stage disease) in China (IV) in April 2025 (NCT06897579)
  • 01 Apr 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial in Small cell lung cancer (Combination therapy; First line therapy) in China (IV), in March 2025 (NCT06897579)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top